Trade Summary

2 months ago, Manning Paul B, serving as Dir at Candel Therapeutics, Inc. (CADL), purchased 550,458 shares at $5.45 per share, for a total transaction value of $2,999,996.00. Following this transaction, Manning Paul B now holds 5,748,279 shares of CADL.

This purchase represents a 11.00% increase in Manning Paul B's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, February 23, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, February 26, 2026, 3 days after the trade was made.

Candel Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.